Trial Profile
An Open-label, Single Arm Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Nemiralisib (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 19 Jun 2020 Status changed from active, no longer recruiting to completed.
- 25 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2020 Planned End Date changed from 31 May 2020 to 15 Jun 2020.